Amyotrophic Lateral Sclerosis (ALS) Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Amyotrophic Lateral Sclerosis (ALS) Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Type (Rilutek (Riluzole), Edaravone (Radicava))
5.2.2. By Treatment Type (Physical Therapy, Speech Therapy, Medication, Respiratory Therapy, Others)
5.2.3. By End-Users (Hospitals & Clinics, Research and Academic institutes, others)
5.2.4. By Region
5.2.5. By Company (2022)
5.3. Market Map
6. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Type
6.2.2. By Treatment Type
6.2.3. By End-Users
6.2.4. By Country
6.3. Asia Pacific: Country Analysis
6.3.1. China Amyotrophic Lateral Sclerosis (ALS) Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Type
6.3.1.2.2. By Treatment Type
6.3.1.2.3. By End-Users
6.3.2. India Amyotrophic Lateral Sclerosis (ALS) Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Type
6.3.2.2.2. By Treatment Type
6.3.2.2.3. By End-Users
6.3.3. Australia Amyotrophic Lateral Sclerosis (ALS) Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Type
6.3.3.2.2. By Treatment Type
6.3.3.2.3. By End-Users
6.3.4. Japan Amyotrophic Lateral Sclerosis (ALS) Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Drug Type
6.3.4.2.2. By Treatment Type
6.3.4.2.3. By End-Users
6.3.5. South Korea Amyotrophic Lateral Sclerosis (ALS) Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Drug Type
6.3.5.2.2. By Treatment Type
6.3.5.2.3. By End-Users
7. Europe Amyotrophic Lateral Sclerosis (ALS) Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Type
7.2.2. By Treatment Type
7.2.3. By End-Users
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. France Amyotrophic Lateral Sclerosis (ALS) Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Type
7.3.1.2.2. By Treatment Type
7.3.1.2.3. By End-Users
7.3.2. Germany Amyotrophic Lateral Sclerosis (ALS) Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Type
7.3.2.2.2. By Treatment Type
7.3.2.2.3. By End-Users
7.3.3. Spain Amyotrophic Lateral Sclerosis (ALS) Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Type
7.3.3.2.2. By Treatment Type
7.3.3.2.3. By End-Users
7.3.4. Italy Amyotrophic Lateral Sclerosis (ALS) Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Type
7.3.4.2.2. By Treatment Type
7.3.4.2.3. By End-Users
7.3.5. United Kingdom Amyotrophic Lateral Sclerosis (ALS) Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Type
7.3.5.2.2. By Treatment Type
7.3.5.2.3. By End-Users
8. North America Amyotrophic Lateral Sclerosis (ALS) Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Type
8.2.2. By Treatment Type
8.2.3. By End-Users
8.2.4. By Country
8.3. North America: Country Analysis
8.3.1. United States Amyotrophic Lateral Sclerosis (ALS) Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Type
8.3.1.2.2. By Treatment Type
8.3.1.2.3. By End-Users
8.3.2. Mexico Amyotrophic Lateral Sclerosis (ALS) Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Type
8.3.2.2.2. By Treatment Type
8.3.2.2.3. By End-Users
8.3.3. Canada Amyotrophic Lateral Sclerosis (ALS) Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Type
8.3.3.2.2. By Treatment Type
8.3.3.2.3. By End-Users
9. South America Amyotrophic Lateral Sclerosis (ALS) Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Type
9.2.2. By Treatment Type
9.2.3. By End-Users
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Amyotrophic Lateral Sclerosis (ALS) Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Type
9.3.1.2.2. By Treatment Type
9.3.1.2.3. By End-Users
9.3.2. Argentina Amyotrophic Lateral Sclerosis (ALS) Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Type
9.3.2.2.2. By Treatment Type
9.3.2.2.3. By End-Users
9.3.3. Colombia Amyotrophic Lateral Sclerosis (ALS) Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Type
9.3.3.2.2. By Treatment Type
9.3.3.2.3. By End-Users
10. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Type
10.2.2. By Treatment Type
10.2.3. By End-Users
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Amyotrophic Lateral Sclerosis (ALS) Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Type
10.3.1.2.2. By Treatment Type
10.3.1.2.3. By End-Users
10.3.2. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Type
10.3.2.2.2. By Treatment Type
10.3.2.2.3. By End-Users
10.3.3. UAE Amyotrophic Lateral Sclerosis (ALS) Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Type
10.3.3.2.2. By Treatment Type
10.3.3.2.3. By End-Users
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions
13. Global Amyotrophic Lateral Sclerosis (ALS) Market: SWOT Analysis
14. Porter?s Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. PESTLE Analysis
16. Competitive Landscape
16.1. Sanofi S.A
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (In case of listed companies)
16.1.5. Recent Developments
16.1.6. SWOT Analysis
16.2. Brainstorm Cell Therapeutics Inc.
16.2.1. Business Overview
16.2.2. Company Snapshot
16.2.3. Products & Services
16.2.4. Financials (In case of listed companies)
16.2.5. Recent Developments
16.2.6. SWOT Analysis
16.3. Biogen Inc.
16.3.1. Business Overview
16.3.2. Company Snapshot
16.3.3. Products & Services
16.3.4. Financials (In case of listed companies)
16.3.5. Recent Developments
16.3.6. SWOT Analysis
16.4. Bausch Health Cos Inc.
16.4.1. Business Overview
16.4.2. Company Snapshot
16.4.3. Products & Services
16.4.4. Financials (In case of listed companies)
16.4.5. Recent Developments
16.4.6. SWOT Analysis
16.5. F Hoffmann-la Roche Ltd
16.5.1. Business Overview
16.5.2. Company Snapshot
16.5.3. Products & Services
16.5.4. Financials (In case of listed companies)
16.5.5. Recent Developments
16.5.6. SWOT Analysis
16.6. Ionis Pharmaceuticals Inc.
16.6.1. Business Overview
16.6.2. Company Snapshot
16.6.3. Products & Services
16.6.4. Financials (In case of listed companies)
16.6.5. Recent Developments
16.6.6. SWOT Analysis
16.7. Mylan Pharma Inc.
16.7.1. Business Overview
16.7.2. Company Snapshot
16.7.3. Products & Services
16.7.4. Financials (In case of listed companies)
16.7.5. Recent Developments
16.7.6. SWOT Analysis
16.8. Sun Pharmaceutical Industries Inc
16.8.1. Business Overview
16.8.2. Company Snapshot
16.8.3. Products & Services
16.8.4. Financials (In case of listed companies)
16.8.5. Recent Developments
16.8.6. SWOT Analysis
16.9. Orion Pharma A/S
16.9.1. Business Overview
16.9.2. Company Snapshot
16.9.3. Products & Services
16.9.4. Financials (In case of listed companies)
16.9.5. Recent Developments
16.9.6. SWOT Analysis
16.10. AB Science SA
16.10.1. Business Overview
16.10.2. Company Snapshot
16.10.3. Products & Services
16.10.4. Financials (In case of listed companies)
16.10.5. Recent Developments
16.10.6. SWOT Analysis
17. Strategic Recommendations
18. About Us & Disclaimer